Diffuse Large B-Cell Lymphoma (DLBCL): Therapeutic Updates and Best Practices (CME)

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma (NHL), making up just under a third of NHL cases. In the U.S., there are roughly 7 cases of DLBCL per 100,000 patients per year, with an average age of presentation at 64 years old. The pathophysiology of DLBCL is complex and not fully understood; but is characterized by a widespread increase of very large, mature B-cells arising from various gene mutations. DLBCL is heterogenous group of tumors and includes many diverse subtypes based on location, presence of other cells within the tumor, and whether the patient has other related illnesses. Advanced age, immunodeficiency, and Epstein-Barr virus are associated risk factors for DLBCL.

Program Objectives:

1. Recognize and describe those characteristics that play a role in determining the staging, prognosis, and diagnosis of diffuse large B-cell lymphoma (DLBCL)
2. Describe the most approaches to DLBCL management and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence and evidence-based treatment guidelines supporting them
3. Summarize the risk-benefit profiles of current and emerging therapies for the treatment of DLBCL
4. Describe the challenges and barriers to care associated with treating patients with DLBCL

Credit Designation:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians. ScientiaCME designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.